Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (NASDAQ: TWST) and Adicet Bio (NASDA: ACET) have announced a collaboration aimed at accelerating the discovery of gamma delta T cell therapies targeting five undisclosed cancer-related antigens. Twist will utilize its proprietary antibody discovery technologies to aid in engineering immune cells with novel chimeric antigen receptors (CARs), enhancing Adicet's pipeline. The agreement includes an upfront technology licensing fee, clinical and regulatory milestones, and product royalties, emphasizing the partnership's potential in advancing T cell therapies for cancer treatment.
Twist Bioscience Corporation (NASDAQ:TWST) has entered a research collaboration with Boehringer Ingelheim to discover therapeutic antibodies using Twist's proprietary antibody libraries. This partnership enables the identification and optimization of potential antibody candidates across multiple targets. Twist will receive an upfront payment for each program and could earn up to $710 million in milestone payments related to clinical and regulatory success. The collaboration highlights Twist’s capabilities in antibody development aimed at personalized treatments.
Twist Bioscience Corporation (NASDAQ:TWST) announced a collaboration with Boehringer Ingelheim to utilize Twist's proprietary antibody libraries for discovering therapeutic antibodies. The agreement allows for a wide range of disease targets and grants Boehringer Ingelheim exclusive rights to develop any resulting antibodies. Twist will receive upfront payments for each program and could earn up to $710 million in milestone payments. Both companies aim to create new, personalized treatments for patients.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will present at the Baird 2021 Global Healthcare Conference on September 14 at 4:20 p.m. Eastern Time. This virtual event will be available for live streaming on the company's investor relations website and archived for 30 days post-event. Twist Bioscience specializes in high-quality synthetic DNA production using a proprietary silicon-based platform, serving multiple industries, including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CFO Jim Thorburn and CCO Patrick Finn will host a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Summit on August 11th at 2:00 p.m. P.T. in Laguna Beach, California. The event will be webcast live and available for replay for 30 days after the chat. Twist Bioscience is a leader in synthetic biology, utilizing its unique silicon-based platform to produce a variety of synthetic DNA products for healthcare, agriculture, and research sectors.
Twist Bioscience (TWST) reported strong third-quarter results for fiscal 2021, ending June 30, with total revenues of $35.0 million, a 65% increase year-over-year. Orders reached $39.1 million, up from $24.7 million in Q3 2020. Despite a net loss of $40.0 million, or $0.82 per share, the company increased its revenue guidance, driven by growth in DNA synthesis and NGS tools. Key developments included the acquisition of iGenomX and advancements in NGS workflows, supporting a rising customer base of approximately 1,800 clients.
Twist Bioscience Corporation (NASDAQ: TWST) has appointed Dr. Melissa Starovasnik to its board of directors. With nearly 30 years of experience in protein and antibody drug discovery, including significant roles at Genentech, Dr. Starovasnik is expected to provide valuable strategic guidance for Twist's biopharma expansion. CEO Emily M. Leproust highlighted her expertise as crucial for leveraging Twist's DNA platform to support a diverse customer base. Dr. Starovasnik aims to enhance collaboration with Twist's leadership to capitalize on biopharmaceutical opportunities and further strengthen the company's market position.
Twist Bioscience (Nasdaq: TWST) and MOLCURE Inc. have announced a collaboration that resulted in the generation of potent antibodies for an undisclosed oncology target, enhancing Twist's internal pipeline. This partnership leverages Twist's antibody discovery and optimization technology alongside MOLCURE's AI capabilities. Both companies expressed optimism about the potential advancements in drug discovery from this collaboration. Twist continues to innovate in synthetic biology, aiming for long-term growth across various sectors, including healthcare and agriculture.
Twist Bioscience Corporation (Nasdaq: TWST) has commenced shipping synthetic RNA reference controls for the SARS-CoV-2 Delta variants B.1.617.2 and B.1.617.3, which are swiftly spreading globally. CEO Emily M. Leproust emphasized the ongoing pandemic challenges and the company’s commitment to offering essential synthetic DNA and RNA products aimed at combating COVID-19. Twist's offerings include NGS assays and a broad range of infectious disease panels. The synthetic controls are sequence-verified and cover the entire viral genome, addressing the evolution of SARS-CoV-2.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its fiscal 2021 third-quarter financial results on August 6, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET to discuss the results and provide a business update. Twist, known for its innovative synthetic DNA technology, is focused on various sectors including healthcare and agriculture. Investors can access the financial results via the Investor Relations section of the company's website.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
